The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
You can now vote if you have shares on HL
Why would any investor not want 4D to relist?
Hi everyone,
I’ve been invested in synairgen for a while, and the failed P3 trial hit me hard. I still hope this company will deliver on its potential. But in my head I thought if we aren’t on a platform trial by winter I’m not going to be checking up daily in this like I have been doing.
It’s really sad the company hasn’t been able to get on a trial. If a loved one was coming down with any viral respiratory illness, I would 100% want them to have access to this drug, and for that reason I hold my investment, but I think we are truly in the middle of the night with this one. It’s always darkest before the dawn, I still hold hope but it’s really testing at the moment.
Good luck, and hopefully next time I’m on here I will find we did make it to a trial.
Merry Christmas everyone.
Completely anecdotal but working in a health care setting, rates seem to be picking up over here too. People are testing and reporting less but it’s still going around.
The NHS could be in for a very tough winter. If that’s due to flu, COVID or both, the need for a broad spectrum antiviral has gone nowhere.
Just watched the presentation. When it mentions the sun group of depressed or anxious patients, what are they getting at here?
Surely a useful subgroup is obesity or age. Depression or anxiety, didnt see that coming. Although more data is better than nothing.
From what I can see it hasn’t been updated since August.
The winter is coming and with it another covid wave. Surely trials will be conducted and Synairgen must be in mind when they are.
With a fun raise etc yes the SP will be hit hard, but right now I believe there is more chance of a JV or platform trial than that.